How many 8-K filings has Beam Therapeutics Inc. filed?

Beam Therapeutics Inc. (BEAM) has 12 8-K (Current Event Report) filings on record, spanning Jan 2024 to May 2026.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Beam Therapeutics Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Beam Therapeutics Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Beam Therapeutics Inc. (BEAM) — 8-K Filings

All 8-K filings from Beam Therapeutics Inc.. Browse 12 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (12)

8-K Filing — May 7, 2026
8-K Filing — Dec 11, 2025
Beam Therapeutics Reports Unregistered Equity Sale — Jul 3, 2025 Risk: medium
Beam Therapeutics Inc. announced on July 1, 2025, an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or
Beam Therapeutics Files 8-K on Security Holder Vote — Jun 6, 2025 Risk: medium
Beam Therapeutics Inc. filed an 8-K on June 6, 2025, reporting on a matter submitted to a vote of its security holders on June 4, 2025. The filing does not disc
Pfizer to Acquire Beam Therapeutics for $13B — Mar 10, 2025 Risk: medium
Beam Therapeutics Inc. announced on March 10, 2025, that it has entered into a definitive agreement to be acquired by Pfizer Inc. for approximately $13.0 billio
Beam Therapeutics Files 8-K on Financials and Operations — Jan 13, 2025 Risk: low
Beam Therapeutics Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures re
Beam Therapeutics Files 8-K — Dec 9, 2024 Risk: low
Beam Therapeutics Inc. filed an 8-K on December 9, 2024, reporting an event that occurred on December 7, 2024. The filing pertains to Regulation FD Disclosure,
Beam Therapeutics Announces Board and Executive Changes — Dec 6, 2024 Risk: medium
Beam Therapeutics Inc. announced on December 5, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departur
Beam Therapeutics Appoints New Director, Discloses Officer Compensation — Dec 4, 2024 Risk: low
Beam Therapeutics Inc. announced on December 2, 2024, a change in its board of directors. Dr. David R. Walt has been appointed as a new director, effective imme
Beam Therapeutics Adds Harvard Professor to Board — Jul 15, 2024 Risk: low
Beam Therapeutics Inc. announced on July 11, 2024, the election of Dr. Sarah E. Fortune to its Board of Directors. Dr. Fortune is a distinguished professor and
Beam Therapeutics Files 8-K on Shareholder Votes — Jun 10, 2024 Risk: low
Beam Therapeutics Inc. filed an 8-K on June 10, 2024, reporting on matters submitted to a vote of its security holders as of June 5, 2024. The filing details th
Beam Therapeutics Files 8-K on Operations, Financial Condition — Jan 8, 2024
Beam Therapeutics Inc. filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition,' 'Regulation FD Disclosure,' and 'Other

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX